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METHODS FOR PREVENTING OXIDATIVE 
STRESS INJURY OF A TISSUE BY A 
FOLATE-TEMPOL CONJUGATE 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
2 
This application claims priority to PCT/US2010/049642 
filed 21 Sep. 2010 and U.S. Provisional Application 61/245, 10 
439 filed on 24 Sep. 2009, which applications are hereby 
incorporated by this reference in their entireties. 
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TECHNICAL FIELD 
15 
20 
or salts or prodrugs thereof. 
Another aspect of the disclosure encompasses composi-
tions comprising a pharmaceutically active Folate-TEMPOL 
conjugate, wherein the Folate-TEMPOL conjugate has the 
formula: 
The present disclosure is generally related to methods of 
preventing oxidative stress injury induced by renal ischemia- 25 
reperfusion by a Folate-TEMPOL conjugate 
SUMMARY 
The present disclosure encompasses compos1t10ns and 
therapeutic methods for the prevention of oxidative stress 
injury that arises from ischemia and reperfusion of tissues. 
The compositions of the present disclosure may also be useful 
in preventing such injury that arises from other causes and 
stress to tissues, and may be useful in treating damaged tis-
sues to enhance or initiate repair of the injury. 
One aspect of the disclosure, therefore, encompasses meth-
ods for reducing oxidative stress injury of a tissue compris-
ing: delivering to a human or animal subject a pharmaceuti-
cally acceptable composition comprising an effective amount 
ofa Folate-TEMPOL conjugate, thereby reducing oxidative 
stress injury to a tissue. 
In embodiments of this aspect of the disclosure, the phar-
maceutically acceptable composition may further comprise a 
pharmaceutically acceptable carrier. 
In some embodiments of the methods of this aspect of the 
disclosure, the oxidative stress injury to a tissue of the subject 
animal or human can be caused by renal ischemia. 
In some embodiments of this aspect of the disclosure, the 
oxidative stress injury to a tissue of the animal or human 
subject can be caused by ischemia-reperfusion on a kidney. 
In some embodiments of the methods of this aspect of the 
invention, the pharmaceutically acceptable composition may 
be delivered to the human or animal subject before the induc-
tion of oxidative stress injury to a tissue. 
In some embodiments of the methods of this aspect of the 
invention, the pharmaceutically acceptable composition is 
delivered to the human or animal subject before a renal 
ischemia or the reperfusion thereof. 
In embodiments of the methods ofthis aspect of the inven-
tion, the Folate-TEMPOL conjugate has the formula: 
30 
In some embodiments of this aspect of the disclosure, the 
composition may further comprise a pharmaceutically 
35 
acceptable carrier. 
BRIEF DESCRIPTION OF THE FIGURES 
Further aspects of the present disclosure will be more 
readily appreciated upon review of the detailed description of 
40 its various embodiments, described below, when taken in 
conjunction with the accompanying drawings. 
FIG. 1 shows data on superoxide concentration in cultured 
HK-2 cells measured by DHE-HPLC (n=3) between 
untreated and LPS treated mice. Tempo! and tempol-folate 
45 incubation effectively scavenged superoxide production 
compared with LPS treated cells. Superoxide concentration 
was normalized to protein concentration. Data represent 
mean and SEM. This data provides evidence that folate con-
jugation with tempo! does not affect the ability of tempo! to 
50 scavenge superoxide. 
FIG. 2 shows data on urinary albumin excretion measured 
in urine samples taken over 24 hours from C57bl/6J mice 
comparing albumin excretion in saline treated mice with 
sham treated mice, n=8-14 and comparing tempol-folate 
55 treated mice with saline treated mice, n=8- l 4. Samples were 
collected 48 hours following 30 minute bilateral renal 
ischemia-reperfusion. Data represent mean and SEM. These 
data support the hypothesis that tempol-folate prevents kid-
ney injury more effectively than free tempo! in ischemia-
60 reperfusion injury. 
FIG. 3 shows plasma creatinine levels measured 48 hours 
following 30 minute bilateral renal ischemia-reperfusion of 
plasma creatinine in saline and tempo! treated mice with 
sham mice, n=7-14. Data represent mean and SEM. These 
65 data indicate that tempol-folate preserves glomerular filtra-
tion rate from ischemia-reperfusion more effectively than 
unconjugated tempo!. 
US 8,815,860 B2 
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FIG. 4 shows data on plasma blood urea nitrogen (BUN) in 
saline treated mice with sham treated mice, n=7-14 and in 
saline treated mice and tempo! treated mice. BUN was mea-
sured 48 hours following 30 minutes bilateral renal ischemia-
reperfusion. Data represent mean and SEM. These data show 
that the proximal tubule function is protected from ischemic 
injury by tempol-folate compared with free tempo!. 
FIG. SA shows a representative electron spin resonance 
plot produced by tempo!. FIG. SB shows a representative plot 
from tempol-folate conjugate. 
FIG. SC shows a tempo! standard curve measured by ESR. 
FIG. SD shows supernatant tempo! and tempol-folate con-
centration after incubation with human proximal tubule (HK-
2) cells quantified by electron spin resonance (ESR). 
10 
FIG. SE shows HK-2 cell concentration of tempo! and 15 
tempol-folate quantified by ESR. 
FIG. SF shows data on tissue tempo! and tempol-folate 
concentration quantified by ESR in mice after 48 hour intra-
venous infusion. Data represent mean and SEM. These data 
display that tempol-folate becomes more concentrated in cul- 20 
tured proximal tubule cells and in vivo in kidneys of mice 
compared with tempo! indicating that folate conjugation 
leads to greater uptake into the cell, specifically in tissues rich 
with folate receptors such as the intestines and the kidney. 
FIG. 6A shows representative images of mouse kidneys 2 25 
hours post-ischemia incubated with hydrocyanine-3, images 
taken at 20x magnification. 
FIG. 6B shows data on quantification of fluorescent inten-
sity ofhydrocyanine-3 treated mouse kidney sections. 
FIG. 6C shows data on whole kidney superoxide concen- 30 
tration measured by DHE-HPLC normalized to protein con-
centration, n=4. 
FIG. 6D shows representative nitrotyrosine staining in kid-
ney sections 48 hours post-ischemia, images taken at 20x 
magnification. Data represent mean and SEM. These data 35 
show that tempol-folate is more effective at scavenging super-
oxide in the kidney after 30 minutes renal ischemia. 
FIG. 7 shows representative hematoxylin and eosin (H&E) 
staining of kidney sections harvested 48 hours post-ischemia. 
These images display that renal structure is protected from 40 
renal ischemia-reperfusion injury by tempol-folate treatment 
more efficiently than by tempo! treatment. 
The drawings are described in greater detail in the descrip-
tion and examples below. 
The details of some exemplary embodiments of the meth- 45 
ods and systems of the present disclosure are set forth in the 
description below. Other features, objects, and advantages of 
the disclosure will be apparent to one of skill in the art upon 
examination of the following description, drawings, 
examples and claims. It is intended that all such additional 50 
systems, methods, features, and advantages be included 
within this description, be within the scope of the present 
disclosure, and be protected by the accompanying claims. 
4 
the upper and lower limit of that range and any other stated or 
intervening value in that stated range, is encompassed within 
the disclosure. The upper and lower limits of these smaller 
ranges may independently be included in the smaller ranges 
and are also encompassed within the disclosure, subject to 
any specifically excluded limit in the stated range. Where the 
stated range includes one or both of the limits, ranges exclud-
ing either or both of those included limits are also included in 
the disclosure. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this disclosure 
belongs. Although any methods and materials similar or 
equivalent to those described herein can also be used in the 
practice or testing of the present disclosure, the preferred 
methods and materials are now described. 
All publications and patents cited in this specification are 
herein incorporated by reference as if each individual publi-
cation or patent were specifically and individually indicated 
to be incorporated by reference and are incorporated herein 
by reference to disclose and describe the methods and/or 
materials in connection with which the publications are cited. 
The citation of any publication is for its disclosure prior to the 
filing date and should not be construed as an admission that 
the present disclosure is not entitled to antedate such publi-
cation by virtue of prior disclosure. Further, the dates of 
publication provided could be different from the actual pub-
lication dates that may need to be independently confirmed. 
As will be apparent to those of skill in the art upon reading 
this disclosure, each of the individual embodiments described 
and illustrated herein has discrete components and features 
which may be readily separated from or combined with the 
features of any of the other several embodiments without 
departing from the scope or spirit of the present disclosure. 
Any recited method can be carried out in the order of events 
recited or in any other order that is logically possible. 
Embodiments of the present disclosure will employ, unless 
otherwise indicated, techniques of medicine, organic chem-
istry, biochemistry, molecular biology, pharmacology, and 
the like, which are within the skill of the art. Such techniques 
are explained fully in the literature. 
It must be noted that, as used in the specification and the 
appended claims, the singular forms "a," "an," and "the" 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "a support" 
includes a plurality of supports. In this specification and in the 
claims that follow, reference will be made to a number of 
terms that shall be defined to have the following meanings 
unless a contrary intention is apparent. 
As used herein, the following terms have the meanings 
ascribed to them unless specified otherwise. In this disclo-
sure, "comprises," "comprising," "containing" and "having" 
and the like can have the meaning ascribed to them in U.S. 
patent law and can mean "includes," "including," and the like; 
DETAILED DESCRIPTION 
Before the present disclosure is described in greater detail, 
it is to be understood that this disclosure is not limited to 
particular embodiments described, and as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
embodiments only, and is not intended to be limiting, since 
the scope of the present disclosure will be limited only by the 
appended claims. 
55 "consisting essentially of' or "consists essentially" or the 
like, when applied to methods and compositions encom-
passed by the present disclosure refers to compositions like 
those disclosed herein, but which may contain additional 
structural groups, composition components or method steps 
Where a range of values is provided, it is understood that 
each intervening value, to the tenth of the unit of the lower 
limit unless the context clearly dictates otherwise, between 
60 (or analogs or derivatives thereof as discussed above). Such 
additional structural groups, composition components or 
method steps, etc., however, do not materially affect the basic 
and novel characteristic( s) of the compositions or methods, 
compared to those of the corresponding compositions or 
65 methods disclosed herein. "Consisting essentially of' or 
"consists essentially" or the like, when applied to methods 
and compositions encompassed by the present disclosure 
US 8,815,860 B2 
5 
have the meaning ascribed in U.S. patent law and the term is 
open-ended, allowing for the presence of more than that 
which is recited so long as basic or novel characteristics of 
that which is recited is not changed by the presence of more 
than that which is recited, but excludes prior art embodi-
ments. 
Prior to describing the various embodiments, the following 
definitions are provided and should be used unless otherwise 
indicated. 
Definitions 
The terms "administer", "administering", or "administra-
tion", as used herein refer to either directly administering a 
compound or pharmaceutically acceptable salt of the com-
pound or a composition to an animal, or administering a 
prodrug derivative or analog of the compound or pharmaceu-
tically acceptable salt of the compound or composition to the 
animal, which can form an equivalent amount of the com-
pound within the animal's body. 
The term "subject" as used herein includes, without limi-
tation, a human, mouse, rat, guinea pig, dog, cat, horse, cow, 
pig, monkey, chimpanzee, baboon, or rhesus monkey. In one 
embodiment, the animal is a mammal. 
The term "TEMPO L" as used herein refers to the superox-
ide dismutase mimetic 4-hydroxy-2,2,6,6-tetramethylpiperi-
dine 1-oxyl. 
The term "folate" as used herein refers to "N-[p-[[(2-
amino-4-hydroxy-6-pteridinyl) methyl]-amino ]benzoyl]-L-
glutamate". 
A Folate-TEMPOL conjugate refers to any molecule that 
contains a TEMPOL moiety and a folate moiety. The Folate-
TEMPOL conjugate may be in the form of a derivative pro-
drug or salt thereof. The TEMPOL and folate moieties are 
typically substituted and coupled together and separated by 
linking groups containing amides, esters, peptides, hydrocar-
bons, glycols, polyethylene glycols, or other polymeric 
groups and the like. 
6 
radicals and peroxides. Some of the less reactive of these 
species (such as superoxide) can be converted by oxidoreduc-
tion reactions with transition metals or other redox cycling 
compounds (including quinones) into more aggressive radi-
cal species that can cause extensive cellular damage. The 
major portion of long term effects is inflicted by damage on 
DNA. Most of these oxygen-derived species are produced at 
a low level by normal aerobic metabolism and the damage 
they cause to cells is constantly repaired. However, under the 
10 severe levels of oxidative stress that cause necrosis, the dam-
age causes ATP depletion, preventing controlled apoptotic 
death and causing the cell to simply fall apart. 
One source of reactive oxygen under normal conditions in 
humans is the leakage of activated oxygen from mitochondria 
15 during oxidative phosphorylation. Enzymes capable of pro-
ducing superoxide are xanthine oxidase, NADPH oxidases 
and cytochromes P450. Hydrogen peroxide is produced by a 
wide variety of enzymes including several oxidases. Reactive 
oxygen species play important roles in cell signalling, a pro-
20 cess termed redox signaling. Thus, to maintain proper cellular 
homeostasis, a balance must be struck between reactive oxy-
gen production and consumption. 
The best studied cellular antioxidants are the enzymes 
superoxide dismutase (SOD), catalase, and glutathione per-
25 oxidase. Less well studied (but probably just as important) 
enzymatic antioxidants are the peroxiredoxins and the 
recently discovered sulfiredoxin. Other enzymes that have 
antioxidant properties (though this is not their primary role) 
include paraoxonase, glutathione-S transferases, and alde-
30 hyde dehydrogenases. 
Oxidative stress contributes to tissue injury following irra-
diation and hyperoxia. It is suspected to be important in 
neurodegenerative diseases including Lou Gehrig's disease 
(aka MND or ALS), Parkinson's disease, Alzheimer's dis-
35 ease, and Huntington's disease. Oxidative stress is thought to 
be linked to certain cardiovascular disease, since oxidation of 
LDL in the vascular endothelium is a precursor to plaque 
formation. Oxidative stress also plays a role in the ischemic 
cascade due to oxygen reperfusion injury following hypoxia. The term "oxidative stress" as used herein refers to an 
imbalance between the production of reactive oxygen and a 
biological system's ability to readily detoxify the reactive 
intermediates or easily repair the resulting damage. Distur-
bances in the normal redox state within a living cell can cause 
toxic effects through the production of peroxides and free 
radicals that damage all components of the cell, including 45 
proteins, lipids, and DNA. 
40 This cascade includes both strokes and heart attacks. Oxida-
tive stress has also been implicated in chronic fatigue syn-
drome. 
The term "effective amount" as used herein refers to an 
amount of a compound or pharmaceutically acceptable salt of 
a compound that, when administered to an animal, is effective 
to prevent, to at least partially ameliorate, or to cure, a con-
In humans, oxidative stress is involved in many diseases, 
such as atherosclerosis, Parkinson's disease, Heart Failure, 
Myocardial Infarction, Alzheimer's disease, Fragile X Syn-
drome, and chronic fatigue syndrome, but short-term oxida- 50 
tive stress may also be important in prevention of aging by 
induction ofa process named mitohormesis. Reactive oxygen 
species can be beneficial, as they are used by the immune 
system as a way to attack and kill pathogens. Reactive oxygen 
species are also used in cell signaling. This is dubbed redox 55 
signaling. 
In chemical terms, oxidative stress is a large rise (becoming 
less negative) in the cellular reduction potential, or a large 
decrease in the reducing capacity of the cellular redox 
couples, such as glutathione. The effects of oxidative stress 60 
depend upon the size of these changes, with a cell being able 
dition from which the animal suffers or is suspected to suffer. 
The term "pharmaceutically acceptable salt", as used 
herein, refers to salts derived from organic and inorganic 
acids of a compound described herein. Exemplary salts 
include, but are not limited to, sulfate, citrate, acetate, oxalate, 
chloride, hydrochloride, bromide, hydrobromide, iodide, 
nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, 
lactate, salicylate, acid citrate, tartrate, oleate, tannate, pan-
tothenate, bitartrate, ascorbate, succinate, maleate, gentisi-
nate, fumarate, gluconate, glucaronate, saccharate, formate, 
benzoate, glutamate, methanesulfonate, ethanesulfonate, 
benzenesulfonate, p-toluenesulfonate, camphorsulfonate, 
napthalenesulfonate, propionate, succinate, fumarate, male-
ate, malonate, mandelate, malate, phthalate, and pamoate. 
The term "pharmaceutically acceptable salt" as used herein 
also refers to a salt of a compound described herein having an 
acidic functional group, such as a carboxylic acid functional 
group, and a base. Exemplary bases include, but are not 
to overcome small perturbations and regain its original state. 
However, more severe oxidative stress can cause cell death 
and even moderate oxidation can trigger apoptosis, while 
more intense stresses may cause necrosis. 
A particularly destructive aspect of oxidative stress is the 
production of reactive oxygen species, which include free 
65 limited to, hydroxide of alkali metals including sodium, 
potassium, and lithium; hydroxides of alkaline earth metals 
such as calcium and magnesium; hydroxides of other metals, 
US 8,815,860 B2 
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such as aluminum and zinc; ammonia, organic amines such as 
unsubstituted or hydroxyl-substituted mono-, di-, ortri-alky-
lamines, dicyclohexylamine; tributyl amine; pyridine; N-me-
thyl, N-ethylamine; diethylamine; triethylamine; mono-, 
bis-, or tris-(2-0H-(C1 -C6)-alkylamine), such as N,N-dim-
ethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl) 
amine; N-methyl-D-glucamine; morpholine; thiomorpho-
line; piperidine; pyrrolidine; and amino acids such as 
arginine, lysine, and the like. The term "pharmaceutically 
acceptable salt" also includes hydrates of a compound 
described herein. 
The term "pharmaceutically acceptable carrier" as used 
herein refers to a diluent, adjuvant, excipient, or vehicle with 
which a heterodimeric probe of the disclosure is administered 
and which is approved by a regulatory agency of the Federal 
or a state government or listed in the U.S. Pharmacopeia or 
other generally recognized pharmacopeia for use in animals, 
and more particularly in humans. Such pharmaceutical carri-
ers can be liquids, such as water and oils, including those of 
petroleum, animal, vegetable or synthetic origin, such as pea-
nut oil, soybean oil, mineral oil, sesame oil and the like. The 
pharmaceutical carriers can be saline, gum acacia, gelatin, 
starch paste, talc, keratin, colloidal silica, urea, and the like. 
When administered to a patient, the heterodimeric probes and 
pharmaceutically acceptable carriers preferably should be 
sterile. Water is a useful carrier when the heterodimeric probe 
8 
preferably a synergistic combination. Synergy, as described, 
for example, by Chou and Talalay, Adv. Enzyme Regul. 1984, 
22:27-55, occurs when the effect of the compounds when 
administered in combination is greaterthan the additive effect 
of the compounds when administered alone as a single agent. 
In general, a synergistic effect is most clearly demonstrated at 
sub-optimal concentrations of the compounds. Synergy can 
be in terms of lower cytotoxicity, increased effect, or some 
other beneficial effect of the combination compared with the 
10 individual components. 
The present agents may be systemically administered, e.g., 
orally, in combination with a pharmaceutically acceptable 
excipient such as an inert diluent or an assimilable edible 
carrier. They may be enclosed in hard or soft shell gelatin 
15 capsules, may be compressed into tablets or may be incorpo-
rated directly with the food of the patient's diet. For oral 
therapeutic administration, the active compound may be 
combined with one or more excipients and used in the form of 
ingestible tablets, buccal tablets, troches, capsules, elixirs, 
20 suspensions, syrups, wafers, and the like. The percentage of 
the compositions and preparations may, of course, be varied 
and may conveniently be, but not limited to, between about 1 
to about 60% of the weight of a given unit dosage form. The 
amount of active compound in such therapeutically useful 
25 compositions is such that an effective dosage level will be 
obtained. 
is administered intravenously. Saline solutions and aqueous 
dextrose and glycerol solutions can also be employed as 
liquid carriers, particularly for injectable solutions. Suitable 
pharmaceutical carriers also include excipients such as glu- 30 
case, lactose, sucrose, glycerol monostearate, sodium chlo-
ride, glycerol, propylene, glycol, water, ethanol and the like. 
The present compositions, if desired, can also contain minor 
amounts of wetting or emulsifying agents, or pH buffering 
agents. The present compositions advantageously may take 35 
the form of solutions, emulsion, sustained-release formula-
tions, or any other form suitable for use. 
The tablets, troches, pills, capsules, and the like may also 
contain the following: binders such as gum tragacanth, aca-
cia, corn starch or gelatin; excipients such as dicalcium phos-
phate; a disintegrating agent such as corn starch, potato 
starch, alginic acid and the like; a lubricant such as magne-
sium stearate; and a sweetening agent such as sucrose, fruc-
tose, lactose or aspartame or a flavoring agent such as pep-
permint, oil of wintergreen or cherry flavoring may be added. 
When the unit dosage form is a capsule, it may contain, in 
addition to materials of the above type, a liquid carrier, such 
as a vegetable oil or a polyethylene glycol. Various other 
materials may be present as coatings or to otherwise modify 
the physical form of the solid unit dosage form. For instance, 
tablets, pills or capsules may be coated with gelatin, wax, 
shellac or sugar and the like: A syrup or elixir may contain the 
The term "physiologically acceptable" as used herein 
refers to a composition that, in contact with a cell, isolated 
from a natural source or in culture, or a tissue of a host, has no 40 
toxic effect on the cell or tissue. 
The terms "include", "for example", "such as", and the like 
are used illustratively and are not intended to limit the present 
invention. 
The terms "treating" or "treatment" as used herein refer to 
the treatment of a disease-state in an animal or human subject, 
and may include: (a) preventing the disease, abnormal physi-
ological, anatomical, or biochemical-state from occurring in 
the subject, in particular, when such subject may not yet have 
been diagnosed as having or displaying such as state; (b) 
inhibiting the disease, abnormal physiological, anatomical, 
or biochemical-state, e.g., arresting it development; and/or ( c) 
relieving the disease, abnormal physiological, anatomical, or 
biochemical-state, e.g., causing regression of the disease, 
abnormal physiological, anatomical, or biochemical-state 
until a desired endpoint is reached. Treating also includes the 
amelioration of a symptom of a disease (e.g., lessen the pain 
or discomfort), wherein such amelioration may or may not be 
directly affecting the disease (e.g., cause, transmission, 
expression, etc.). 
The term "therapeutically effective amount" as used herein 
includes an amount of a compound according to the present 
disclosure that is effective when administered alone or in 
combination to a indication listed herein. The term "thera-
peutically effective amount" also includes an amount of the 
combination of compounds claimed that is effective to treat 
the desired indication. The combination of compounds is 
active compound, sucrose or fructose as a sweetening agent, 
methyl and propylparabens as preservatives, a dye and fla-
voring such as cherry or orange flavor. Of course, any material 
45 used in preparing any unit dosage form should be pharma-
ceutically acceptable and substantially non-toxic in the 
amounts employed. In addition, the active compound may be 
incorporated into sustained-release preparations and devices. 
The active agent may also be administered intravenously or 
50 intraperitoneally by infusion or injection. Solutions of the 
active compound or its salts can be prepared in water, option-
ally mixed with a nontoxic surfactant. Dispersions can also be 
prepared in glycerol, liquid polyethylene glycols, triacetin, 
and mixtures thereof and in oils. U nderordinary conditions of 
55 storage and use, these preparations contain a preservative to 
prevent the growth of microorganisms. 
The pharmaceutical dosage forms suitable for injection or 
infusion can include sterile aqueous solutions or dispersions 
or sterile powders comprising the active ingredient which are 
60 adapted for the extemporaneous preparation of sterile inject-
able or infusible solutions or dispersions, optionally encap-
sulated in liposomes. In all cases, the ultimate dosage form 
should be sterile, fluid and stable under the conditions of 
manufacture and storage. The liquid carrier or vehicle can be 
65 a solvent or liquid dispersion medium comprising, for 
example, water, ethanol, a polyol (for example, glycerol, 
propylene glycol, liquid polyethylene glycols, and the like), 
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vegetable oils, nontoxic glyceryl esters, and suitable mixtures 
thereof. The proper fluidity can be maintained, for example, 
by the formation of liposomes, by the maintenance of the 
required particle size in the case of dispersions or by the use 
of surfactants. The prevention of the action of microorgan-
isms can be brought about by various antibacterial and anti-
fungal agents, for example, parabens, chlorobutanol, phenol, 
sorbic acid, thimerosal, and the like. In many cases, it will be 
preferable to include isotonic agents, for example, sugars, 
buffers or sodium chloride. Prolonged absorption of the 10 
injectable compositions can be brought about by the use in the 
compositions of agents delaying absorption, for example, 
aluminum monostearate and gelatin. 
Sterile injectable solutions are prepared by incorporating 
the active compound in the required amount in the appropri- 15 
ate solvent with several of the other ingredients enumerated 
above, as required, followed by filter sterilization. In the case 
of sterile powders for the preparation of sterile injectable 
solutions, the preferred methods of preparation are vacuum 
drying and the freeze drying techniques, which yield a pow- 20 
der of the active ingredient plus any additional desired ingre-
dient present in the previously sterile-filtered solutions. 
While it is contemplated that the therapeutic compositions 
of the present disclosure are preferably administered under 
controlled conditions whereby the compositions are deliv- 25 
ered to the recipient subject intravenously, it is not intended 
that other routes of administration are excluded, such as a 
bolus injection, inhalation, tablet form and the like, or directly 
to the renal tissues. 
The amount of the agent required for use in treatment will 30 
vary not only with the particular agent selected but also with 
the route of administration, the nature of the condition being 
treated, and the age and condition of the patient and will be 
ultimately at the discretion of the attendant physician or cli-
nician. In general, however, a suitable dose will be in the 35 
range of from (a) about 1.0-100 mg/kg of body weight per 
day, (b) about 10-7 5 mg/kg of body weight per day, and ( c) 
about 5-20 mg per kilogram body weight per day. 
The compounds described herein may be administered in 
the form of prodrugs. A prodrug can include a covalently 40 
bonded carrier which releases the active parent drug when 
administered to a mammalian subject. Prodrugs can be pre-
pared by modifying functional groups present in the com-
pounds in such a way that the modifications are cleaved, 
either in routine manipulation or in vivo, to the parent com- 45 
pounds. Prodrugs include, for example, compounds wherein 
a carboxylic acid group is bonded to any group that, when 
administered to a mammalian subject, cleaves to form a free 
carboxylic acid, e.g., ester of the carboxylic acid. Examples 
of prodrugs include, but are not limited to, ethyl or methyl 50 
esters, ethoxy or methoxy groups in place of a phenol 
hydroxy. Methods of structuring a compound as prodrugs can 
be found in the book of Testa and Mayer, Hydrolysis in Drug 
and Prodrug Metabolism, Wiley (2006). Typical prodrugs 
form the active metabolite by in vivo transformation through 55 
hydrolytic enzymes, the hydrolysis of amide, lactams, pep-
tides, carboxylic acid esters, epoxides or the cleavage of 
esters of inorganic acids. 
10 
contain between 7 to 21 mg of urea nitrogen per 100 ml (7-21 
mg/dL) of blood. Individual laboratories may have different 
reference ranges, and this is because the procedure may vary. 
The most common cause of an elevated BUN, anorexia, is 
poor kidney function, although a serum creatinine level is a 
somewhat more specific measure of renal function (see also 
renal function). A greatly elevated BUN (>60 mg/dL) gener-
ally indicates a moderate-to-severe degree of renal failure. 
Impaired renal excretion of urea may be due to temporary 
conditions such as dehydration or shock, or may be due to 
either acute or chronic disease of the kidneys themselves. 
An elevated BUN in the setting of a relatively normal 
creatinine may reflect a physiological response to a relative 
decrease of blood flow to the kidney (as seen in heart failure 
or dehydration) without indicating any true injury to the kid-
ney. However, an isolated elevation of BUN may also reflect 
excessive formation of urea without any compromise to the 
kidneys. When the ratio of BUN to creatinine is greater than 
20, the patient is suspected of having pre-renal azotemia. This 
means that the pathologic process is unlikely to be due to 
intrinsic kidney damage. 
Because multiple variables can interfere with the interpre-
tation of a BUN value, GFR and creatinine clearance are more 
accurate markers of kidney function. Age, sex, and weight 
will alter the "normal" range for each individual, including 
race. In renal failure or chronic kidney disease (CKD), BUN 
will only be elevated outside "normal" when more than 60% 
of kidney cells are no longer functioning. Hence, more accu-
rate measures of renal function are generally preferred to 
assess the clearance for purposes of medication dosing. BUN 
is reported as mg/dL in the United States. Elsewhere, the 
concentration of urea is reported as mmol/L. Chemical colo-
rimetric tests are Diacetyl Monoxime, Urograph and Modi-
fied Berthelot Enzymatic methods. 
Creatinine 
Creatinine is a break-down product of creatine phosphate 
in muscle, and is usually produced at a fairly constant rate by 
the body (depending on muscle mass). Chemically, creatinine 
is a spontaneously formed cyclic derivative of creatine. Crea-
tinine is chiefly filtered out of the blood by the kidneys, 
though a small amount is actively secreted by the kidneys into 
the urine. There is little or no tubular reabsorption of creati-
nine. However, if the filtering of the kidney is deficient, blood 
levels rise. Therefore, creatinine levels in blood and urine 
may be used to calculate the creatinine clearance (CrCI), 
which reflects the glomerular filtration rate (GFR), The GFR 
is clinically important because it is a measurement of renal 
function. However, in cases of severe renal dysfunction, the 
creatinine clearance rate will be "overestimated" because the 
active secretion of creatinine will account for a larger fraction 
of the total creatinine cleared. 
A more complete estimation of renal function can be made 
when interpreting the blood (plasma) concentration of crea-
tinine along with that of urea. BUN-to-creatinine ratio (the 
ratio of urea to creatinine) can indicate other problems 
besides those intrinsic to the kidney; for example, a urea level 
raised out of proportion to the creatinine may indicate a 
Blood Urea Nitrogen (BUN) Test 60 pre-renal problem such as volume depletion. 
The blood urea nitrogen (BUN) test is a measure of the 
amount of nitrogen in the blood in the form of urea, and a 
measurement of renal function. Urea is a substance secreted 
by the liver, and removed from the blood by the kidneys. 
The liver produces urea in the urea cycle as a waste product 
of the digestion of protein. Normal human adult blood should 
Measuring serum creatinine is a simple test and it is the 
most commonly used indicator of renal function. A rise in 
blood creatinine levels is observed only with marked damage 
to functioning nephrons. Therefore, this test is not suitable for 
65 detecting early stage kidney disease. A better estimation of 
kidney function is given by the creatinine clearance test. 
Creatinine clearance can be accurately calculated using 
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serum creatinine concentration and some or all of the follow-
ing variables: sex, age, weight, and race as suggested by the 
American Diabetes Association without a 24 hour urine col-
lection. Some laboratories will calculate the CrCl if written 
on the pathology request form; and, the necessary age, sex, 
and weight are included in the patient information. In the 
United States, creatinine is typically reported inmg/dL, while 
in Canada and Europe mmol/liter may be used. 1 mg/dL of 
creatinine is 88.4 µmol/L. 
12 
The typical human reference ranges are 0.5 to 1.0 mg/dL 
(about 45-90 µmol/L) for women and 0.7 to 1.2 mg/dL (60-
110 µmol/L) for men. While a baseline serum creatinine of 
2.0 mg/dL (150 µmol/L) may indicate normal kidney function 
in a male body builder, a serum creatinine of 1.2 mg/dL (110 
µmol/L) can indicate significant renal disease in a frail old 
woman. 
age of reperfusion injury is due in part to the inflammatory 
response of damaged tissues. White blood cells carried to the 
area by the newly returning blood release a host of inflam-
matory factors such as interleukins as well as free radicals in 
response to tissue damage. The restored blood flow reintro-
duces oxygen within cells that damages cellular proteins, 
DNA, and the plasma membrane. Damage to the cell's mem-
brane may in turn cause the release of more free radicals. Such 
reactive species may also act indirectly in redox signaling to 
10 turn on apoptosis. Leukocytes may also build up in small 
capillaries, obstructing them and leading to more ischemia. 
Reperfusion injury plays a part in the brain's ischemic 
cascade, which is involved in stroke and brain trauma. Similar 
15 failure processes are involved in brain failure following rever-
sal of cardiac arrest; control of these processes is the subject 
of ongoing research. Repeated bouts of ischemia and reper-
fusion injury also are thought to be a factor leading to the 
formation and failure to heal of chronic wounds such as 
The term "ischemia" as used herein refers to a restriction in 
blood supply, generally due to factors in the blood vessels, 
with resultant damage or dysfunction of tissue. It may also be 
spelled ischaemia or ischaamia. Rather than hypoxia (a more 20 
general term denoting a shortage of oxygen, usually a result 
of lack of oxygen in the air being breathed), ischemia is an 
absolute or relative shortage of the blood supply to an organ, 
pressure sores and diabetic foot ulcers. Continuous pressure 
limits blood supply and causes ischemia, and the inflamma-
tion occurs during reperfusion. As this process is repeated, it 
eventually damages tissue enough to cause a wound. 
In prolonged ischemia ( 60 minutes or more), hypoxanthine 
is formed as breakdown product of ATP metabolism. The 
enzyme xanthine dehydrogenase acts in reverse, i.e. as a 
xanthine oxidase as a result of the higher availability of oxy-
gen. This oxidation results in molecular oxygen being con-
verted into highly reactive superoxide and hydroxyl radicals. 
Xanthine oxidase also produces uric acid, which may act as 
both a prooxidant and as a scavenger of reactive species such 
as peroxynitrite. Excessive nitric oxide produced during rep-
erfusion reacts with superoxide to produce the potent reactive 
species peroxynitrite. Such radicals and reactive oxygen spe-
cies attack cell membrane lipids, proteins, and glycosami-
noglycans, causing further damage. They may also initiate 
specific biological processes by redox signaling. 
Description 
The present disclosure encompasses compos1t10ns and 
i.e. a shortage of oxygen, glucose and other blood-borne 
components. A relative shortage means the mismatch of 25 
blood supply (oxygen/fuel delivery) and blood request for 
adequate metabolism of tissue. Ischemia results in tissue 
damage because of a lack of oxygen and nutrients. Ultimately, 
this can cause severe damage because of the potential for a 
build-up of metabolic wastes. Ischemia can also be described 30 
as an inadequate flow ofblood to a part of the body, caused by 
constriction or blockage of the blood vessels supplying it. 
This can be due to, but is not limited to, such as hypoglycemia 
(lower than normal level of blood glucose); tachycardia (ab-
normally rapid beating of the heart); atherosclerosis (lipid- 35 
laden plaques obstructing the lumen of arteries); hypotension 
(low blood pressure, e.g. in septic shock, heart failure); 
thromboembolism (blood clots); outside compression of a 
blood vessel, e.g. mechanically by pressure, severing of a 
blood vessel, implantation of a transplanted organ, surgery, 40 
by a tumor, and the like; embolism (foreign bodies in the 
circulation, e.g. anmiotic fluid embolism); sickle cell disease 
(abnormally shaped red blood cells); induced g-forces which 
restrict the blood flow and force the blood to the extremities of 
the body, as in acrobatics and military flying; and localized 
extreme cold, such as by frostbite, ice, or improper cold 
compression therapy. 
45 their uses for the prevention of ischemia-reperfusion injuries 
that result in oxidative stress injuries in, but not limited to, the 
kidney. The compositions of the disclosure provide a conju-
gate between TEMPOL and Folic acid (folate ). In an illustra-
tive example, the folate moiety of the conjugate is preferen-
Since oxygen is mainly bound to hemoglobin in red blood 
cells, insufficient blood supply causes tissue to become 
hypoxic, or, if no oxygen is supplied at all, anoxic. In very 
aerobic tissues such as heart and brain, at body temperature 
necrosis due to ischemia usually takes about 3-4 hours before 
becoming irreversible. This and typically some collateral cir-
culation to the ischemic area accounts for the efficacy of 
"clot-buster" drugs given for stroke and heart attack within 
this time period. However, complete cessation of oxygenation 
of such organs for more than 20 minutes typically results in 
irreversible damage. 
Restoration of blood flow after a period of ischemia can 
actually be more damaging than the ischemia. Reintroduction 
of oxygen causes a greater production of damaging free radi-
cals, resulting in reperfusion injury. With reperfusion injury, 
necrosis can be greatly accelerated. Low doses of hydrogen 
sulfide (H2 S) have been found to protect against regional 
myocardial ischemia-reperfusion injury. 
The term "reperfusion" as used herein refers to the resto-
ration of blood flow to a tissue following ischemia. The dam-
50 tially able to bind to the folate receptors of the renal proximal 
tubule, thereby also delivering the potent anti-oxidant to the 
luminal cells. The conjugate may then be internalized by the 
receiving cell, resulting in a reduction in the level of NO-
induced free radicals that could otherwise result in oxidative 
55 damage to the cells. By preemptively administering the con-
jugates of the disclosure to the kidney before the formation of 
a ischemia, NO-induced injury that results from the subse-
quent reperfusion of the organ is reduced. 
The discovery herein described demonstrates that the con-
60 jugate ofTEMPOL and folate is more potent than folate on its 
own in reducing ischemic-reperfusion damage to a tissue, in 
this case, the kidney proximal tubules. Ischemic-induced 
superoxide is significantly reduced by the Folate-TEMPOL 
conjugate, compared to the use ofTEMPOL alone. While not 
65 wishing to be bound by any one theory, the data shows that the 
Folate-TEMPOL conjugate has a greater affinity for proximal 
tubule cells than does TEMPOL alone. 
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The effects of the Folate-TEMPOL conjugate of the 
present disclosure on renal ischemic-reperfusion injury pre-
vention were observed by intravenously administering TEM-
POL or Folate-TEMPOL. The renal artery was then clamped 
for about 30 mins, followed by 48 hours of reperfusion. 
Parameters measured as indicators of renal tubule injury 
included creatinine, BUN, and albumin levels both before and 
after ischemia.Also measured were the TEMPOL and Folate-
TEMPOL concentrations in the plasma and the kidney. 
Conjugating folate to TEMPOL results in a marked reduc-
tion in the three parameters that, when elevated, indicate renal 
oxidative damage. 
The data shows that Folate-TEMPOL inhibits superoxide 
as efficiently as TEMPOL alone, and that Folate-TEMPOL 
accumulates in cultured proximal tubule cells to a greater 
extent than un-conjugated Tempo!. 
Post-ischemic increases in plasma albumin, creatinine and 
BUN were reduced by providing the Folate-TEMPOL con-
jugate to the subject before the ischemia-reperfusion, and that 
the reduction was greater than if TEMPOL alone was used. 
These results indicate that Folate-TEMPOL is more effective 
at preventing post-ischemic renal injury than is TEMPOL, 
and that specifically targeting proximal tubule oxidative dam-
age could prevent the development of renal failure as a result 
of ischemia-reperfusion in settings such as renal transplant. 
The use of the folate conjugate reduces the anti-oxidant 
dose required and by targeting vulnerable sites reduces non-
specific antioxidant effects. It is further contemplated that the 
conjugate of the present disclosure may also be used to reduce 
the oxidative stress damage in organs and tissues other than 
14 
those of the renal system, and especially in those systems 
where there are folate receptors to facilitate the transport of 
the conjugate into the intracellular environment to inactivate 
the superoxide free radicals. 
One aspect of the disclosure, therefore, encompasses meth-
ods for reducing oxidative stress injury of a tissue compris-
ing: delivering to a human or animal subject a pharmaceuti-
cally acceptable composition comprising an effective amount 
ofa Folate-TEMPOL conjugate, thereby reducing oxidative 
10 stress injury to a tissue of the human or animal subject. 
In embodiments of this aspect of the disclosure, the phar-
maceutically acceptable composition may further comprise a 
pharmaceutically acceptable carrier. 
In some embodiments of the methods of this aspect of the 
15 disclosure, the oxidative stress injury to a tissue of the subject 
animal or human can be caused by renal ischemia. 
In some embodiments of this aspect of the disclosure, the 
oxidative stress injury to a tissue of the subject animal or 
human can be caused by ischemia-reperfusion on a kidney of 
20 the subject human or animal. 
In some embodiments of the methods of this aspect of the 
invention, the pharmaceutically acceptable composition may 
be delivered to the subject human or animal before the induc-
tion of oxidative stress injury to a tissue of the subject animal 
25 orhuman. 
In some embodiments of the methods of this aspect of the 
invention, the pharmaceutically acceptable composition is 
delivered to the subject human or animal before a renal 
ischemia or the reperfusion thereof. 
In embodiments of the methods ofthis aspect of the inven-
tion, the Folate-TEMPOL conjugate has the formula: 
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prodrugs or salts thereof, wherein n is 1 to 10, 10 to 100, 100 
to 1,000, and 1,000 to 10,000. 
Another aspect of the disclosure encompasses composi-
tions comprising a pharmaceutically active Folate-TEMPOL 5 
conjugate. 
In some embodiments of this aspect of the disclosure, the 
composition may further comprise a pharmaceutically 
acceptable carrier. 10 
In some embodiments, it is contemplated that composi-
tions disclosed herein can be administered to subject before, 
during or after certain medical procedures, such as, organ 
transplants (heart, kidneys, liver, lungs, pancreas, intestine, 15 
and thymus) or other surgeries that reduce blood flow (car-
diovascular surgery). The subject may be receiving or donat-
ing the organ. 
In some embodiments, it is contemplated that composition 20 
disclosed herein can be used in biological (organ, tissue, or 
cell) storage mediums, typically aqueous solutions main-
tained at or below room temperatures, which may contain 
other ingredients such as, but not limited to, salts (sodium 25 
chloride, sodium lactate, calcium chloride, potassium chlo-
ride), amino acids, saccharides, polysaccharides ( dextran, 
chondroitin, hydroxyethyl starch), vitamins (thiamine, ascor-
bic acid, calciferol, riboflavin, pyridoxine, tocopherol, cabal-
30 
amins, phylloquinone, pantothenic acid, biotin, niacin, folic 
acid) and/or adenosine triphosphate or precursors ( adenosine, 
inosine, and adenine). 
The specific examples below are to be construed as merely 35 
illustrative, and not !imitative of the remainder of the disclo-
sure in any way whatsoever. Without further elaboration, it is 
believed that one skilled in the art can, based on the descrip-
tion herein, utilize the present disclosure to its fullest extent. 
40 
All publications recited herein are hereby incorporated by 
reference in their entirety. 
It should be emphasized that the embodiments of the 
present disclosure, particularly, any "preferred" embodi-
45 
ments, are merely possible examples of the implementations, 
merely set forth for a clear understanding of the principles of 
the disclosure. Many variations and modifications may be 
made to the above-described embodiment(s) of the disclosure 
50 
without departing substantially from the spirit and principles 
of the disclosure. All such modifications and variations are 
intended to be included herein within the scope of this dis-
closure, and the present disclosure and protected by the fol-
lowing claims. 
The following examples are put forth so as to provide those 
55 
of ordinary skill in the art with a complete disclosure and 
description of how to perform the methods and use the com-
positions and compounds disclosed and claimed herein. 60 
Efforts have been made to ensure accuracy with respect to 
numbers (e.g., amounts, temperature, etc.), but some errors 
and deviations should be accounted for. Unless indicated 
otherwise, parts are parts by weight, temperature is in ° C., 65 
and pressure is at or near atmospheric. Standard temperature 
and pressure are defined as 20° C. and 1 atmosphere. 
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EXAMPLES 
Example 1 
Synthesis of Folate-TEMPOL Conjugate (1) 
Folate 
A I EDCl,HOBt ;Pr2NEt 
0 
Tempo! 
Tempol-Folate 
The Folate-TEMPOL conjugate (1) was synthesized fol-
lowing modified esterification strategy described by Crich et 
al., (2007) J. Am. Chem. Soc. 129: 12106, (S-24-25), incor-
porated herein by reference in its entirety. To an oven-dried 
100 mL round-bottomed flask fitted with a magnetic stir-bar 
and septum under nitrogen were added 4-amino-2,2,6,6-tet-
ramethylpiperidinyloxy, free radical (0.32 g, 2.02 mmol, 1.0 
equiv.), folic acid (1.00 g, 2.26 mmol, 1.0 equiv.), N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride 
(0.47 g, 2.48 mmol, 1.2 equiv.) and 1-hydroxybenzotriazole 
(0.438 g, 0.34 mmol, 1.2 equiv.) followed by approximately 
30 mL dry CH2 Cl2 and 10 mL dry DMF and cooled to 0° C. 
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N,N-diisopropylethylamine (1.14 g, 8.82 nnnol, 4.3 equiv.) 
was added drop-wise. The reaction mixture was then allowed 
to warm to room temperature and stirred overnight. The reac-
tion mixture was diluted up with CH2 Cl2 , washed with satu-
rated aqueous NaHC03 and brine and dried over Na2S04 . 
The solvent was evaporated and the crude radical dried under 
vacuum. The Folate-TEMPOL conjugate was further purified 
by recrystalization from ethanol. 
Data regarding the activity of this Folate-TEMPOL Con- 10 
jugate is provided in the figures. Typically, cultured human 
proximal tubule (HK-2) cells were treated with LPS to induce 
superoxide free radical formation. The level of superoxide is 
indicated by the formation of 2-hydroxyethidium as 
described, for example by Zielonka et al., (2008) Nat. Proto- 15 
cols 3: 8-21, incorporated herein by reference in its entirety. 
Example 2 
Synthesis ofFolate-PEG-TEMPOL Conjugate (2) 
COOR 0 
/ Nn HO ~ H I ~O~ OH #NH 
o :XN:( N ~ I 
H2NAN ::::,...N 
COOR 0 
--
0 /n N ~ N-0 0 ~ H I Q y ~O~ OH # NH 
0 o o :XN:( N ~ I A::::,.... H2N N N 
COOR 0 
--
. /N o o :XNI 0 N ~ I 
A::::,.... H2N N N 
60 
One uses procedures as provided for in Zalipsky et al, 
FESS Letters 353 (1994) 71-74 and Esmaeili et al., Journal of 
Drug Targeting, (2008) 16(5): 415-423. One couples folate 
with a monoamino polyethylene glycol (PEG). One activates 
the hydroxyl of PEG the with N,N'-disuccinimidyl carbonate 65 
then reacts with 4-amino-2,2,6,6-tetramethylpiperidinyloxy, 
free radical. 
18 
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Example 3 
Synthesis ofFolate-PLA-TEMPOL Conjugate (3) 
One uses procedures as provided for in Zalipsky et al, 
FESS Letters 353 (1994) 71-74 and Esmaeili et al., Journal of 40 
Drug Targeting, (2008) 16(5): 415-423. One couples folate 
with a diamino alkyl which is optionally monoamine substi-
tuted with a protecting group. Removal of the protecting 
group provides a folate-amine. Polylactic acid (PLA) is 
coupled to the amine. One activates the hydroxyl of PLA with 45 
N,1 \1 '-sisuccinimidyl carbonate then reacts with 4-amino-2, 
2,6,6-tetramethylpiperidinyloxy, free radical. 
The invention claimed is: 
1. A pharmaceutical composition comprising a conjugate 
having the formula: 50 
55 
60 
or an ester of the carboxylic acid or pharmaceutically 65 
acceptable salt thereof and a pharmaceutically accept-
able carrier. 
20 
2. A biological storage solution comprising a conjugate 
having the formula: 
or an ester of the carboxylic acid or salt thereof, wherein the 
solution further comprising a component selected from a 
salt, amino acid, vitamin, a saccharide, a polysaccha-
ride, and adenosine triphosphate or precursor. 
3. A method of treating ischemic injury comprising admin-
istering a pharmaceutical composition of claim 1 to a subject. 
4. The method of claim 3, wherein the subject is diagnosed 
with reduced kidney function. 
5. The method of claim 3, wherein the subject received an 
organ transplant. 
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6. The method of claim 3, wherein the pharmaceutical 
composition is delivered to the subject before, after, or during 
a medical procedure. 
* * * * * 
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